Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!
Fibrocell Science Inc FCSC stock gained 15 percent Monday morning in reaction to the autologous cell-based therapeutic company's announcement of interim results from an ongoing clinical trial. The company's Phase 1/2 clinical trial of its FCX-007 gene therapy for recessive dystrophic epidermolysis bullosa was "well tolerated up to 52 weeks post-administration" with no product-related adverse events reported.
Avenue Therapeutics Inc ATXI gained more than 3 percent. The therapeutics company said its first pivotal Phase 3 trial of IV tramadol achieved its primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours (SPID48) compared to a placebo.
General Electric Company GE gained more than 2.5 percent after the conglomerate giant reached an agreement to merge its transportation unit with Westinghouse Air Brake Technologies Corp WAB. As part of the agreement, General Electric will receive $2.9 billion in cash and hold a 50.1 percent ownership stake in the new entity.
Acacia Communications, Inc. ACIA gained nearly 4 percent -- a move that may be attributed to easing tensions between the U.S. and Chinese governments. A trade war between the two countries is "on hold," which may bode well for Acacia who derived 30 percent of its revenue from China's ZTE.
QUALCOMM, Inc. QCOM was trading higher by more than 1 percent after the company announced a partnership with Facebook, Inc. FB. As part of the new partnership, Qualcomm and Facebook will work together to deliver high-speed internet connectivity with Facebook's Terragraph technology through Qualcomm's 60GHz technology.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
